Porton Pharma Solutions Ltd(300363) february 28 announced the performance express of 2021. Last year, the company achieved an operating revenue of 3.105 billion yuan, a year-on-year increase of 49.87%; The net profit attributable to the parent company was 524 million yuan, a year-on-year increase of 61.49%; After deduction, the parent company returned 503 million yuan, with an increase of 74.42% and earnings per share of 0.97 yuan.
It is understood that in 2021, with the continuous enrichment and expansion of customer pipelines and product pipelines, as well as the further improvement of R & D technology capability and product delivery capability, the company’s overall business for China and international markets achieved sustained and rapid growth. This is also the third consecutive year of high performance growth since the company further promoted the strategic transformation of cdmo end-to-end one-stop service platform and entered the performance inflection point in 2018. In 2019, the company achieved an operating revenue of 1.551 billion yuan, a year-on-year increase of 30.93%; The net profit attributable to the parent company was 186 million yuan, a year-on-year increase of 49.04%; The net profit attributable to the parent company after deduction was 162 million yuan, an increase of 124.97%. In 2020, the company achieved a total operating revenue of 2.072 billion yuan, a year-on-year increase of 33.56%; The net profit attributable to the parent company was 324 million yuan, a year-on-year increase of 74.84%; The net profit attributable to the parent company after deduction was 290 million yuan, an increase of 79.01%.
For three consecutive years, the company’s net profit after deducting non-profit has increased by more than 70%.
It is worth noting that during the reporting period, the company’s preparation cdmo business and gene cell cdmo business were still in the stage of business expansion and capacity-building, reducing the net profit of the company’s consolidated statements by 106 million yuan in total; At the same time, the industry related joint-stock companies with strategic layout are still in the loss stage, reducing the net profit of the consolidated statements by 31 million yuan. After excluding the above effects, the net profit attributable to the parent company will reach 661 million yuan, with a year-on-year increase of 80.11%; The net profit after deducting non-profit was 639 million yuan, an increase of 92.81%.
Porton Pharma Solutions Ltd(300363) at the same time, it is also decided to use the remaining raised funds of about 335 million yuan, which have not been clearly used, to increase capital to Jiangxi Boteng Pharmaceutical Co., Ltd., a wholly-owned subsidiary, for the construction of its “phase I of multi-functional pharmaceutical intermediates and APIs construction project”, and increase production capacity to undertake the production and delivery of more high-value intermediates and APIs projects. The overall construction period of the project is 22 months. According to the calculation of the feasibility study, the pre tax static payback period (including the construction period) is 6.58 years, and the pre tax internal rate of return is 21.86%.
In addition, the company’s wholly-owned subsidiary Porton pharmaceutical chemicals GmbH (boten Switzerland Co., Ltd.) also plans to use its own funds of DKK 4 million to establish a wholly-owned secondary subsidiary Porton pharmaceuticals Denmark APS (boten Denmark Co., Ltd.) in Denmark to further strengthen the company’s overseas business expansion.
